http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 16:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+ARCH+Venture+Fund+XII%2C+L.P./26930214.html si-local-file:///var/storage/secattach/20260814/26930214.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+ARCH+Venture+Fund+XII%2C+L.P./26930214.html Fri, 14 Aug 2026 16:08:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+ARCH+Venture+Fund+XII%2C+L.P./26930214.html si-local-file:///var/storage/secattach/20260814/26930214.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+ARCH+Venture+Fund+XII%2C+L.P./26930214.html Fri, 14 Aug 2026 16:08:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Parabilis+Medicines%2C++++++For%3A+Jun+30/26921044.html si-local-file:///var/storage/secattach/20260813/26921044.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Parabilis+Medicines%2C++++++For%3A+Jun+30/26921044.html Thu, 13 Aug 2026 16:10:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Parabilis+Medicines%2C++++++For%3A+Jun+30/26921044.html si-local-file:///var/storage/secattach/20260813/26921044.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Parabilis+Medicines%2C++++++For%3A+Jun+30/26921044.html Thu, 13 Aug 2026 16:10:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+13/26916406.html si-local-file:///var/storage/secattach/20260813/26916406.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+13/26916406.html Thu, 13 Aug 2026 07:19:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+13/26916406.html si-local-file:///var/storage/secattach/20260813/26916406.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+13/26916406.html Thu, 13 Aug 2026 07:19:00 -0400 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html <p align="center"><em>Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors </em></p> <p align="center"><em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&apos;s proprietary Helicon</em><em>TM</em><em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties</em><br/></p> <p align="center"><em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030</em> <br/></p> <p align="left">CAMBRIDGE, Mass., Aug. http://www.streetinsider.com/Globe+Newswire/Parabilis+Medicines+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Updates/26916225.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 O.20026344 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+FMR+LLC/26881340.html si-local-file:///var/storage/secattach/20260806/26881340.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+FMR+LLC/26881340.html Thu, 06 Aug 2026 10:39:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+FMR+LLC/26881340.html si-local-file:///var/storage/secattach/20260806/26881340.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Parabilis+Medicines%2C+++++++++++++++++++Filed+by%3A+FMR+LLC/26881340.html Thu, 06 Aug 2026 10:39:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Jul+20++Filed+by%3A+Shah+Rajeev+M./26802462.html si-local-file:///var/storage/secattach/20260722/26802462.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Jul+20++Filed+by%3A+Shah+Rajeev+M./26802462.html Wed, 22 Jul 2026 16:56:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Jul+20++Filed+by%3A+Shah+Rajeev+M./26802462.html si-local-file:///var/storage/secattach/20260722/26802462.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Jul+20++Filed+by%3A+Shah+Rajeev+M./26802462.html Wed, 22 Jul 2026 16:56:00 -0400 O.57149208 PBLS http://www.streetinsider.com/New+Coverage/Leerink+Starts+Parabilis+Medicines+%28PBLS%29+at+Outperform/26732236.html (Updated - July 6, 2026 6:20 AM EDT) <p>Leerink analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Outperform rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of Parabilis Medicines (PBLS) with an OP rating and a $40 PT. The company's lead asset is zolucatetide, a first-in-class β-catenin inhibitor that blocks the β-catenin/TCF interaction, the most downstream node of the Wnt pathway. Zolucatetide is being developed in desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC), colorectal cancer (CRC), and other Wnt/ β-catenin-driven tumors. Historically, the Wnt pathway has been http://www.streetinsider.com/New+Coverage/Leerink+Starts+Parabilis+Medicines+%28PBLS%29+at+Outperform/26732236.html Mon, 06 Jul 2026 06:20:35 -0400 PBLS http://www.streetinsider.com/Analyst+Comments/Leerink+Starts+Parabilis+Medicines+%28PBLS%29+at+Outperform/26732236.html (Updated - July 6, 2026 6:20 AM EDT) <p>Leerink analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Outperform rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of Parabilis Medicines (PBLS) with an OP rating and a $40 PT. The company's lead asset is zolucatetide, a first-in-class β-catenin inhibitor that blocks the β-catenin/TCF interaction, the most downstream node of the Wnt pathway. Zolucatetide is being developed in desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC), colorectal cancer (CRC), and other Wnt/ β-catenin-driven tumors. Historically, the Wnt pathway has been http://www.streetinsider.com/Analyst+Comments/Leerink+Starts+Parabilis+Medicines+%28PBLS%29+at+Outperform/26732236.html Mon, 06 Jul 2026 06:20:35 -0400 PBLS http://www.streetinsider.com/New+Coverage/BofA+Securities+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26732270.html <p>BofA Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Buy rating and a price target of $45.00.</p><p>The analyst comments "We initiate coverage of Parabilis Medicines (PBLS) with a Buy and $45 PO. PBLS is a clinical-stage biotech developing therapeutics for previously ‘undruggable’ targets. Underpinned by its novel AI-driven Helicon platform, PBLS is focused on lead asset zolucatetide for non-cancerous desmoid tumors. The company also has an early-stage pipeline including a collaboration with REGN to expand novel antibody-helicon conjugates into new therapeutic areas beyond oncology. Early clinical data for zolu in desmoid tumors demonstrate compelling efficacy http://www.streetinsider.com/New+Coverage/BofA+Securities+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26732270.html Mon, 06 Jul 2026 06:11:10 -0400 PBLS http://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26732270.html <p>BofA Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Buy rating and a price target of $45.00.</p><p>The analyst comments "We initiate coverage of Parabilis Medicines (PBLS) with a Buy and $45 PO. PBLS is a clinical-stage biotech developing therapeutics for previously ‘undruggable’ targets. Underpinned by its novel AI-driven Helicon platform, PBLS is focused on lead asset zolucatetide for non-cancerous desmoid tumors. The company also has an early-stage pipeline including a collaboration with REGN to expand novel antibody-helicon conjugates into new therapeutic areas beyond oncology. Early clinical data for zolu in desmoid tumors demonstrate compelling efficacy http://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26732270.html Mon, 06 Jul 2026 06:11:10 -0400 PBLS http://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+Parabilis+Medicines+%28PBLS%29+at+Outperform/26732180.html <p>Evercore ISI analyst Umer Raffat initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Outperform rating.</p><p>For an analyst ratings summary and ratings history on Parabilis Medicines <a href="http://www.streetinsider.com/rating_history.php?q=PBLS">click here</a>. For more ratings news on Parabilis Medicines <a href="http://www.streetinsider.com/stock_lookup_news.php?q=PBLS&amp;type=analyst">click here</a>.</p><p>Shares of Parabilis Medicines closed at $29.58 yesterday.</p> http://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+Parabilis+Medicines+%28PBLS%29+at+Outperform/26732180.html Mon, 06 Jul 2026 06:04:24 -0400 PBLS http://www.streetinsider.com/New+Coverage/Guggenheim+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26731585.html <p>Guggenheim analyst Michael Schmidt initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Buy rating and a price target of $40.00.</p><p>The analyst comments: “Under leadership of its experienced executive team, PBLS has developed the “Helicon platform”, a peptide-based drug discovery engine producing cell-penetrant helical peptides that can engage historically "undruggable" targets. We believe the platform serves as a differentiated product engine, which PBLS leverages to build a pipeline of wholly owned product candidates addressing difficult, but mechanistically validated cancer targets, and industry R&D collaborations (e.g., with REGN). Lead product candidate zolucatetide, a first-in-class, direct β-catenin inhibitor, is a “pipeline in http://www.streetinsider.com/New+Coverage/Guggenheim+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26731585.html Mon, 06 Jul 2026 02:39:15 -0400 PBLS http://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26731585.html <p>Guggenheim analyst Michael Schmidt initiates coverage on Parabilis Medicines (NASDAQ: PBLS) with a Buy rating and a price target of $40.00.</p><p>The analyst comments: “Under leadership of its experienced executive team, PBLS has developed the “Helicon platform”, a peptide-based drug discovery engine producing cell-penetrant helical peptides that can engage historically "undruggable" targets. We believe the platform serves as a differentiated product engine, which PBLS leverages to build a pipeline of wholly owned product candidates addressing difficult, but mechanistically validated cancer targets, and industry R&D collaborations (e.g., with REGN). Lead product candidate zolucatetide, a first-in-class, direct β-catenin inhibitor, is a “pipeline in http://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+Parabilis+Medicines+%28PBLS%29+at+Buy/26731585.html Mon, 06 Jul 2026 02:39:15 -0400 PBLS